Other

Current branded prescription drug fee

Neurocrine Biosciences Current branded prescription drug fee decreased by 5.3% to $42.90M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 12.9%, from $38.00M to $42.90M. Over 3 years (FY 2022 to FY 2025), Current branded prescription drug fee shows an upward trend with a 18.1% CAGR.

Analysis

StatementBalance Sheet Statement
SectionOther
First reportedQ4 2022
Last reportedQ1 2026May 5, 2026
Metric ID: other_accrued_branded_prescription_drug_fee

Historical Data

12 periods
 Q4 '22Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Value$27.50M$44.50M$45.70M$35.30M$35.30M$42.70M$49.20M$38.00M$38.00M$39.00M$45.30M$42.90M
QoQ Change—+61.8%+2.7%-22.8%+0.0%+21.0%+15.2%-22.8%+0.0%+2.6%+16.2%-5.3%
YoY Change——+66.2%——-4.0%+7.7%+7.6%+7.6%-8.7%-7.9%+12.9%
Range$27.50M – $49.20M
CAGR+17.6%
Avg YoY Growth+10.2%
Median YoY Growth+7.6%

Frequently Asked Questions

What is Neurocrine Biosciences's current branded prescription drug fee?
Neurocrine Biosciences (NBIX) reported current branded prescription drug fee of $42.90M in Q1 2026.
How has Neurocrine Biosciences's current branded prescription drug fee changed year-over-year?
Neurocrine Biosciences's current branded prescription drug fee increased by 12.9% year-over-year, from $38.00M to $42.90M.
What is the long-term trend for Neurocrine Biosciences's current branded prescription drug fee?
Over 3 years (2022 to 2025), Neurocrine Biosciences's current branded prescription drug fee has grown at a 18.1% compound annual growth rate (CAGR), from $27.50M to $45.30M.